M. Maral Mouradian, M.D., is the William Dow Lovett Professor of Neurology at Rutgers - Robert Wood Johnson Medical School, Founding Director of the RWJMS Institute for Neurological Therapeutics, and Vice Chancellor for Faculty Development at Rutgers Biomedical and Health Sciences. Dr. Mouradian obtained her medical degree with distinction from the American University of Beirut and neurology training at the
University of Cincinnati Medical Center. She then joined the US National Institutes of Health (NIH) where she received postdoctoral training in clinical pharmacological research in Parkinson disease (PD) and other neurodegenerative disorders in the laboratory of Thomas N. Chase of the National Institute of Neurological Disorders and Stroke (NINDS). She received additional training in molecular biology under the tutelage of the Nobel Laureate Marshall Nirenberg at the National Health, Lung and Blood Institute. Prior to joining Rutgers, Dr. Mouradian led the Genetic Pharmacology research program of NINDS, NIH. As an internationally recognized physician-scientist, her career focus has been to elucidate the molecular pathogenesis of Parkinson’s disease (PD) and its treatment complications, and to develop therapies both for disease modification and improved symptom control. Her seminal contributions have provided the rationale for the development of continuous therapeutic modalities for PD. To date, she has authored over 200 scholarly publications, edited two books on Parkinson disease, and holds several patents. Her research is funded by multiple grants from the NIH, the Michael J. Fox Foundation for Parkinson’s Research, the American Parkinson Disease Association, and other foundations.
Dr. Mouradian is an elected member of the Alpha Omega Alpha Honor Medical Society, a Fellow of the American Neurological Association, a Fellow of the American Academy of Neurology, and an alumna of the Hedwig van Ameringen Executive Leadership in Academic Medicine (ELAM). She serves on grant review panels for the NIH and other national and international funding agencies, and is a member of the Scientific Advisory Board of the American Parkinson Disease Association. In addition, she is the Editor-in-Chief of the journal Neurotherapeutics and serves on the editorial boards of several other scientific journals. Among her honors are the Excellence in Research Award from the New Jersey Health Foundation, the Outstanding Medical Scientist Award from the Edward J. Ill Excellence in Medicine Foundation, the Rutgers Board of Trustees Award for Excellence in Research, and the NIH Award of Merit.
